Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ESMO open

Showing results (51-60 of 2,241) with videos related to

Pageof 225
Sort By:
ESMO Open|August 11, 2018
Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanomaReinhard Dummer, Olivier Michielin, Mirjam Chantal Nägeli, et al.
ESMO Open|July 19, 2023
In the literature: July 2023V Gambardella, F Gimeno-Valiente, S Roselló, et al.
ESMO Open|May 25, 2024
Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic societyJ Crona, R Lee, P Sobczuk, et al.
ESMO Open|January 1, 2026
Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experienceO E Emiloju, N R Foster, P Shah, et al.
ESMO Open|May 28, 2025
Letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Ethnic difference in BRCT domain response to PARP inhibitorJ H Kim, M C Lim
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|January 3, 2026
Added value of tumor-stroma ratio to postsurgery circulating tumor DNA and pTN stage in risk stratification of patients with stage III colon cancer treated with adjuvant chemotherapyI A Franken, F Heilijgers, M-C E Bakker, et al.
ESMO Open|May 14, 2020
Brief letter of a doctor to his psychologist in the COVID-19 outbreak eraDaniele Santini, Giuseppe Tonini
ESMO Open|May 15, 2020
ESMO Open: news in breast cancer 2019Matteo Lambertini
ESMO Open|May 12, 2020
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancerToshiki Masuishi, Hiroya Taniguchi, Takeshi Kawakami, et al.
Pageof 225

Showing results (51-60 of 2,241) with videos related to

Sort By:
Pageof 225
ESMO Open|August 11, 2018
Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanomaReinhard Dummer, Olivier Michielin, Mirjam Chantal Nägeli, et al.
ESMO Open|July 19, 2023
In the literature: July 2023V Gambardella, F Gimeno-Valiente, S Roselló, et al.
ESMO Open|May 25, 2024
Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic societyJ Crona, R Lee, P Sobczuk, et al.
ESMO Open|January 1, 2026
Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experienceO E Emiloju, N R Foster, P Shah, et al.
ESMO Open|May 28, 2025
Letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Ethnic difference in BRCT domain response to PARP inhibitorJ H Kim, M C Lim
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|January 3, 2026
Added value of tumor-stroma ratio to postsurgery circulating tumor DNA and pTN stage in risk stratification of patients with stage III colon cancer treated with adjuvant chemotherapyI A Franken, F Heilijgers, M-C E Bakker, et al.
ESMO Open|May 14, 2020
Brief letter of a doctor to his psychologist in the COVID-19 outbreak eraDaniele Santini, Giuseppe Tonini
ESMO Open|May 15, 2020
ESMO Open: news in breast cancer 2019Matteo Lambertini
ESMO Open|May 12, 2020
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancerToshiki Masuishi, Hiroya Taniguchi, Takeshi Kawakami, et al.
Pageof 225